comparemela.com
Home
Live Updates
Travere Therapeutics Reports Third Quarter 2023 Financial Results : comparemela.com
Travere Therapeutics Reports Third Quarter 2023 Financial Results
      Received 430 new patient start forms for FILSPARI® in the third quarter of 2023; demand and payer coverage continued to grow             Net product sales of FILSPARI...
Related Keywords
United States
,
Iceland
,
Liechtenstein
,
Norway
,
American
,
Nivi Nehra
,
Deric Dube
,
Naomi Eichenbaum
,
Mirum Pharmaceuticals
,
American Society Of Nephrology Kidney Week
,
Travere Therapeutics Inc
,
Corporate Communications
,
European Union
,
Program Updates
,
Drug Administration
,
Committee For Medicinal Products Human Use
,
Exchange Commission
,
Mission Pharmacal Company
,
Nasdaq
,
European Medicines Agency
,
Week Late Breakers
,
Travere Total Care
,
Continuing Operations
,
Quarter Ended September
,
American Society
,
Nephrology Kidney Week
,
New England Journal
,
New Drug Application
,
Medicinal Products
,
Human Use
,
Conditional Marketing Authorization
,
Inborn Errors
,
Annual Symposium
,
Par Pharmaceutical
,
Acid Product Portfolio
,
Travere Therapeutics
,
Important Safety Information
,
Endothelin Receptor Antagonists
,
Upper Limit
,
Fetal Toxicity
,
Full Prescribing Information
,
Private Securities Litigation Reform Act
,
Months Ended September
,
Markets
,
comparemela.com © 2020. All Rights Reserved.